– Four leading pediatric infectious disease institutions will study M2SR vaccine response in pediatric subjects, a population in which infection rates are often highest – – Collaborative study led by… read more →
– Study will measure immune responses generated by M2SR and high dose vaccine separately and in combination in the highly vulnerable 65-85 years old population – – Funded by the… read more →
MADISON, Wis., January 5, 2022 – FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced that the Company will present at the 40th Annual… read more →
MADISON, Wis., Sept. 7, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced management is scheduled to present at the Baird… read more →
– Data published in the Journal of Infectious Diseases demonstrate that M2SR can protect against a multi-seasonal, seven-year drifted influenza strain – MADISON, Wis., Aug. 2, 2021 /PRNewswire/ — FluGen, Inc., a… read more →